Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Benzthiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 15/20 | 0.41 |
| ▸ | CA2 | P00918 | 15/20 | 0.41 |
| ▸ | CA12 | O43570 | 14/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzthiazide SCHEMBL26257 | 0.95 | ALDH1A1 (0.63) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL1276519 | 0.94 | ALDH1A1 (0.60) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL7217920 | 0.94 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL345215 | 0.94 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL9517821 | 0.94 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL7102453 | 0.94 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL6546528 | 0.94 | ALDH1A1 (0.62) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL23860715 | 0.93 | ALDH1A1 (0.58) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL386952 | 0.93 | ALDH1A1 (0.58) | ALDH1A1KDM4EMEN1NR1I2ABCB11 | |
| Benzthiazide SCHEMBL2376967 | 0.93 | ALDH1A1 (0.58) | ALDH1A1KDM4EMEN1NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872262-B2 | Means and methods for treating bacterial infections | VIB VZW (BE) | 2024-01-16 | — | — | US | claimed |
| WO-2023195009-A1 | GENETICALLY MODIFIED BACTERIA AND USE THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-10-12 | — | — | WO | claimed |
| US-20210077563-A1 | Means and Methods for Treating Bacterial Infections | VIB VZW (BE) | 2021-03-18 | — | — | US | claimed |
| EP-3621979-A1 | MEANS AND METHODS FOR TREATING BACTERIAL INFECTIONS | VIB vzw (BE) | 2020-03-18 | — | — | EP | claimed |
| WO-2018206732-A9 | MEANS AND METHODS FOR TREATING BACTERIAL INFECTIONS | VIB VZW (BE) | 2019-01-10 | — | — | WO | claimed |
| WO-2018206732-A1 | MEANS AND METHODS FOR TREATING BACTERIAL INFECTIONS | VIB VZW (BE) | 2018-11-15 | — | — | WO | claimed |
| EP-2601209-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | Bayer Intellectual Property GmbH (DE) | 2013-06-12 | — | — | EP | claimed |
| WO-2012016960-A1 | GENOMICS OF ACTINOPLANES UTAHENSIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | WO | claimed |
| EP-2245040-A2 | TRANSCRIPTIONAL CONTROL IN ALICYCLOBACILLUS ACIDOCALDARIUS AND ASSOCIATED GENES, PROTEINS, AND METHODS | Battelle Energy Alliance, LLC (US) | 2010-11-03 | — | — | EP | claimed |
| WO-2009137145-A9 | TRANSCRIPTIONAL CONTROL IN ALICYCLOBACILLUS ACIDOCALDARIUS AND ASSOCIATED GENES, PROTEINS, AND METHODS | BATTELLE ENERGY ALLIANCE, LLC (US) | 2009-12-30 | — | — | WO | claimed |
| WO-2009137145-A2 | TRANSCRIPTIONAL CONTROL IN ALICYCLOBACILLUS ACIDOCALDARIUS AND ASSOCIATED GENES, PROTEINS, AND METHODS | BATTELLE ENERGY ALLIANCE, LLC (US) | 2009-11-12 | — | — | WO | claimed |
| US-20090215168-A1 | Transcriptional control in alicyclobacillus acidocaldarius and associated genes, proteins, and methods | BATTELLE ENERGY ALLIANCE, LLC (US) | 2009-08-27 | — | — | US | claimed |
| US-20240229188-A9 | SYSTEMS AND METHODS FOR EXTRACTING RARE EARTH ELEMENTS WITH ENGINEERED MICROORGANISMS | CORNELL UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| US-12006526-B2 | Microorganisms and methods for the production of oxygenated compounds from hexoses | BRASKEM S.A. (BR) | 2024-06-11 | — | — | US | disclosed |
| EP-3518895-B1 | PHOSPHORYLATED TRI-BLOCK COPOLYMERS WITH PATHOGEN VIRULENCE-SUPPRESSING PROPERTIES | UNIV CHICAGO (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240132993-A1 | SYSTEMS AND METHODS FOR EXTRACTING RARE EARTH ELEMENTS WITH ENGINEERED MICROORGANISMS | UNIV CORNELL (US) | 2024-04-25 | — | — | US | disclosed |
| WO-1988003561-A1 | NEW STRAINS OF ESCHERICHIA COLI WHICH ARE HYPERPRODUCTIVE AND/OR HYPEREXCRETIVE OF EXPORTED PROTEINS, PROCESS OF OBTAINING SAID STRAINS AND APPLICATION IN PROTEIN PRODUCTION | INSTITUT MERIEUX (FR) | 1988-05-19 | — | — | WO | disclosed |
| EP-0267110-A1 | Strains of Escherichia coli hyperproducing and/or hyperexcreting exported proteins, method for obtaining these strains and their use in the production of proteins | INSTITUT MERIEUX (FR) | 1988-05-11 | — | — | EP | disclosed |
| EP-0208704-A1 | NEW STRAINS OF $i(ESCHERICHIA COLI) EXCRETORY OF ALKALINE PHOSPHATASE, METHOD FOR OBTAINING SAID STRAINS, METHOD FOR PRODUCING ALKALINE PHOSPHATASE AND DERIVED HYBRID PROTEIN | INSTITUT MERIEUX (FR) | 1987-01-21 | — | — | EP | disclosed |
| WO-1986004089-A1 | NEW STRAINS OF ESCHERICHIA COLI EXCRETORY OF ALKALINE PHOSPHATASE, METHOD FOR OBTAINING SAID STRAINS, METHOD FOR PRODUCING ALKALINE PHOSPHATASE AND DERIVED HYBRID PROTEIN | INSTITUT MERIEUX S.A. (FR) | 1986-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210077563-A1 | Means and Methods for Treating Bacterial Infections | VIP, MMP8, SLC11A2 | ALDH1A1 4565/4885KDM4E 4630/4885MEN1 3072/4885 |
| US-11872262-B2 | Means and methods for treating bacterial infections | VIP, MMP8, SLC11A2 | ALDH1A1 4565/4885KDM4E 4630/4885MEN1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.